Stockscreener 앱 받기
113.05
2.07%
2.29
시간 외 거래:
110.00
-3.05
-2.70%
전일 마감가:
$110.76
열려 있는:
$116.4
하루 거래량:
1.60M
Relative Volume:
2.15
시가총액:
$2.87B
수익:
$302.00K
순이익/손실:
$-117.10M
주가수익비율:
-10.16
EPS:
-11.13
순현금흐름:
$-129.13M
1주 성능:
+10.84%
1개월 성능:
+78.20%
6개월 성능:
+561.50%
1년 성능:
+974.62%
1일 변동 폭
$110.86
$121.21
1주일 범위
$96.35
$121.21
52주 변동 폭
$10.14
$121.21
Cidara Therapeutics Inc Stock (CDTX) Company Profile
명칭
Cidara Therapeutics Inc
전화
858-752-6170
주소
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
113.05 | 2.81B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-03-12 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-27 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-08 | 개시 | Guggenheim | Buy |
| 2024-08-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 재개 | H.C. Wainwright | Buy |
| 2021-09-22 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 개시 | Aegis Capital | Buy |
| 2019-09-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-07-26 | 개시 | Citigroup | Buy |
| 2017-04-21 | 개시 | Raymond James | Strong Buy |
| 2017-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Ladenburg Thalmann | Buy |
| 2017-04-11 | 재개 | Wedbush | Outperform |
| 2017-02-22 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 업그레이드 | WBB Securities | Sell → Hold |
| 2016-12-21 | 재개 | Leerink Partners | Outperform |
| 2016-12-19 | 개시 | H.C. Wainwright | Buy |
| 2016-09-23 | 다운그레이드 | WBB Securities | Hold → Sell |
| 2015-10-09 | 업그레이드 | WBB Securities | Sell → Hold |
| 2015-05-11 | 개시 | Jefferies | Buy |
| 2015-05-11 | 개시 | Leerink Partners | Outperform |
| 2015-05-11 | 개시 | Needham | Buy |
| 2015-05-11 | 개시 | Wedbush | Outperform |
| 2015-04-23 | 개시 | WBB Securities | Sell |
모두보기
Cidara Therapeutics Inc 주식(CDTX)의 최신 뉴스
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Can machine learning forecast Cidara Therapeutics Inc. recovery2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - The Manila Times
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price target2025 Major Catalysts & Fast Gain Stock Tips - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Trade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Why Cidara Therapeutics Stock Crushed It Today - The Motley Fool
Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade
FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria
CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus
Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria
CDTX Achieves New Heights: What’s Next? - timothysykes.com
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits
Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter
HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus
HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener
Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India
Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus
Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire
Breakthrough Therapy for CD388 Granted; Cidara Advances Phase 3 ANCHOR Trial Expanded to Older Adults - Stock Titan
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stock2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
How Cidara Therapeutics Inc. (20D0) stock performs in volatility spikesJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
Is Cidara Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Big Profit Low Investment - earlytimes.in
Cidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5%Time to Buy? - MarketBeat
Cidara announces funding for non-vaccine flu preventive, CD388 - CIDRAP
How Cidara Therapeutics Inc. (20D0) stock reacts to Fed tightening2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
How buyback programs support Cidara Therapeutics Inc. (20D0) stockCEO Change & Short-Term High Return Ideas - newser.com
Will Cidara Therapeutics Inc. outperform the marketBull Run & Low Drawdown Investment Ideas - newser.com
Biotech Stocks To Research – October 3rd - Defense World
Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring? - ts2.tech
JMP Securities Maintains Cidara Therapeutics (CDTX) Market Outperform Recommendation - Nasdaq
Cidara Therapeutics’ Surprise Surge: What Led the Charge? - timothysykes.com
Biotech Stocks To ResearchOctober 3rd - MarketBeat
Cidara Therapeutics Inc (CDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cidara Therapeutics Inc 주식 (CDTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '25 |
Buy |
44.00 |
2,272,727 |
99,999,988 |
3,365,523 |
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
5.74%
자본화:
|
볼륨(24시간):